
Ginkgo Bioworks Holdings, Inc. (($DNA)) has held its Q3 earnings call. Read on for the main highlights of the call. Ginkgo Bioworks delivered a strongly positive earnings call, with management
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings | 8.50 | 1.40 | 19.68% |
| Name | Price | % Change | |
|---|---|---|---|
| $8.50 | +19.68% |

Ginkgo Bioworks Holdings, Inc. (($DNA)) has held its Q3 earnings call. Read on for the main highlights of the call. Ginkgo Bioworks delivered a strongly positive earnings call, with management

Reports Q3 revenue $28M, consensus $21.51M. The company said, “”Ginkgo now has two core offerings built on one autonomous lab platform. This quarter we announced the sale of an autonomous

16:51 EST Ginkgo Bioworks (DNA) affirms 2026 cash burn target ($150M)-($125M) Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot

Ginkgo Bioworks Holdings ( ($DNA) ) has shared an announcement. Ginkgo Bioworks announced on October 29, 2026, that it will host a post-market presentation and Q&A session to review its

TD Cowen raised the firm’s price target on Ginkgo Bioworks (DNA) to $11 from $9 and keeps a Hold rating on the shares. The firm adjusted targets in the life

The major averages were broadly higher near noon as a rebound in tech stocks helps Wall Street bounce back. The major indexes are still on track for weekly gains, despite

S&P 500 slipped for the second consecutive day while losses on the tech-dominant Nasdaq Composite accelerated, with the index finishing lower by 1.3% on Thursday. Technology was by far the

Ginkgo Bioworks (DNA) announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. Ginkgo’s support was announced today by

Araceli Biosciences and Ginkgo Bioworks (DNA) announced the integration of Araceli’s Endeavor high-content imaging instrument into Nebula, Ginkgo’s autonomous lab in Boston. The Endeavor brings cellular imaging with real-time analysis

Ginkgo Datapoints (DNA) and Apheris announced that the Antibody Developability Consortium has kicked off with its founding members. The Consortium is a new industry collaboration designed to help pharmaceutical and
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $622.89M | $-1.04 | $24.30M | 0.03 | -2.28 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.